Email Address
info@myglp1store.com
Phone Number
+1 470-535-5258
Our Location
8102 Blanding blvd. Jacksonville, FL 32244
info@myglp1store.com
+1 470-535-5258
8102 Blanding blvd. Jacksonville, FL 32244
Price range: $198.00 through $238.00
CagriSema Deal (Cagrilintide + Semaglutide) – Research Combination for Advanced Weight-Related Studies
Note: This dual-compound blend remains investigational. The schedule below reflects publicly available clinical trial frameworks and is provided strictly for research reference only.
Late-stage trials (such as REDEFINE-1) have observed around 20.4% average weight change across ~68 weeks of study.
Research protocols typically evaluate weekly levels including 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg of each peptide.
| Week(s) | Cagrilintide (mg weekly) | Semaglutide (mg weekly) |
|---|---|---|
| 1–4 | 0.25 | 0.25 |
| 5–8 | 0.5 | 0.5 |
| 9–12 | 1.0 | 1.0 |
| 13–16 | 1.7 | 1.7 |
| 17+ | 2.4 | 2.4 |
Finalized regulatory dosing guidelines for commercial availability are still pending.
Escalation in research models should proceed gradually, as gastrointestinal responses may occur during testing.
Applications in studies are performed subcutaneously once per week.
All details provided reflect trial protocol data, not medical recommendations.
This product is intended for research purposes only. It is designated strictly for in vitro testing and laboratory experimentation and is not approved for human or animal consumption. All information provided on this website is for educational and informational purposes only. This product should be handled only by licensed and qualified professionals. It is not a drug, food, or cosmetic, and must not be misbranded, misused, or mislabeled as such.
The CagriSema Weight Loss Deal is designed for researchers who want an effective peptide option for weight-management studies. This bundle supports significant weight reduction with CagriSema by combining GLP-1 and GIP receptor activity. As a result, it helps control appetite, balance blood sugar, and improve metabolic function — all of which are essential for steady and long-lasting progress.
At MYGLP1 Store, we provide high-quality CagriSema peptides sourced from trusted labs. Because of this, our CagriSema Deal offers excellent value for researchers seeking consistent results. Many users report better satiety, fewer cravings, and more stable energy, making this peptide a reliable option for long-term metabolic research.
The CagriSema works by enhancing the body’s GLP-1 and GIP hormone pathways. These pathways help regulate appetite, glucose response, and energy use. When these signals become stronger, appetite decreases, gastric emptying slows, and fat-burning increases. Therefore, many researchers observe noticeable improvements in weight-management markers while using CagriSema in controlled studies.
Researchers should use CagriSema under proper guidance to ensure safe handling and accurate study results. The peptide is typically administered through subcutaneous injection based on the protocol set for your research. When combined with balanced nutrition, hydration, and regular physical activity, the CagriSema can contribute to more consistent and meaningful outcomes in weight-management research.
Transform your research with a bundle that offers both value and reliability. Order the CagriSema Weight Loss Deal – Buy 2 Get 1 Free from MYGLP1 Store today. We deliver trusted GLP-1 and GIP peptide solutions that support clear, measurable, and long-lasting results.
CagriSema Deal (Cagrilintide + Semaglutide) – Research Combination for Advanced Weight-Related Studies
Note: This dual-compound blend remains investigational. The schedule below reflects publicly available clinical trial frameworks and is provided strictly for research reference only.
Late-stage trials (such as REDEFINE-1) have observed around 20.4% average weight change across ~68 weeks of study.
Research protocols typically evaluate weekly levels including 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg of each peptide.
| Week(s) | Cagrilintide (mg weekly) | Semaglutide (mg weekly) |
|---|---|---|
| 1–4 | 0.25 | 0.25 |
| 5–8 | 0.5 | 0.5 |
| 9–12 | 1.0 | 1.0 |
| 13–16 | 1.7 | 1.7 |
| 17+ | 2.4 | 2.4 |
Finalized regulatory dosing guidelines for commercial availability are still pending.
Escalation in research models should proceed gradually, as gastrointestinal responses may occur during testing.
Applications in studies are performed subcutaneously once per week.
All details provided reflect trial protocol data, not medical recommendations.
